These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3580108)

  • 41. Structure activity relationship studies with C-terminal fragments of vasopressin and oxytocin on avoidance behaviors of rats.
    de Wied D; Gaffori O; Burbach JP; Kovács GL; van Ree JM
    J Pharmacol Exp Ther; 1987 Apr; 241(1):268-74. PubMed ID: 3572787
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Arginine-vasopressin content of hippocampus and amygdala during passive avoidance behavior in rats.
    Laczi F; Gaffori O; De Kloet ER; De Wied D
    Brain Res; 1983 Dec; 280(2):309-15. PubMed ID: 6652491
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Memory effects of arginine vasopressin (AVP) and [7-9] fragment of its peptide chain in rats.
    Klimkiewicz T
    Acta Neurobiol Exp (Wars); 2001; 61(4):267-76. PubMed ID: 11905148
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of arginine vasopressin in control of ACTH and LH release during stress.
    Ono N; Bedran de Castro J; Khorram O; McCann SM
    Life Sci; 1985 May; 36(18):1779-86. PubMed ID: 2984509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Septal vasopressin modulates motility and passive avoidance in pinealectomized rats.
    Appenrodt E; Schwarzberg H
    Physiol Behav; 1999 Jul; 66(5):757-61. PubMed ID: 10405103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microinjection of anti-vasopressin serum into limbic structures of the rat brain: effects on passive avoidance responding and on local catecholamine utilization.
    Veldhuis HD; van Wimersma Greidanus TB; Versteeg DH
    Brain Res; 1987 Nov; 425(1):167-73. PubMed ID: 3427417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect of vasopressin on changes in the behavioral reactions of rats induced by psychotropic substances].
    Titov SA; Usenko AB; Ashmarin IP
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1989; 39(2):292-5. PubMed ID: 2750290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vasopressin antagonists block peripheral as well as central vasopressin receptors.
    De Wied D; Gaffori O; Van Ree JM; De Jong W
    Pharmacol Biochem Behav; 1984 Sep; 21(3):393-400. PubMed ID: 6093152
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vasopressin alters female sexual behaviour by acting on the brain independently of alterations in blood pressure.
    Södersten P; Henning M; Melin P; Ludin S
    Nature; 1983 Feb 17-23; 301(5901):608-10. PubMed ID: 6828140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Naloxone influences retention behaviour depending on the degree of novelty inherent to the training situation.
    Del Cerro S; Borrell J
    Physiol Behav; 1985 Nov; 35(5):667-71. PubMed ID: 4080830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor?
    de Wied D; Elands J; Kovács G
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1494-8. PubMed ID: 1847526
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The improvement of memory retention and retrieval of a novel vasopressin fragment analog NC-1900].
    Sato T; Tanaka K; Ohnishi Y; Teramoto T; Hirate K; Nishikawa T
    Nihon Yakurigaku Zasshi; 2002 Nov; 120(1):57P-60P. PubMed ID: 12491780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect on memory processes of anti-vasopressin serum microinjected into the dorsal raphe nucleus: the role of catecholaminergic neurotransmission.
    Kovács GL; Vécsei L; Medve L; Telegdy G
    Exp Brain Res; 1980 Feb; 38(3):357-61. PubMed ID: 6245904
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Further evidence for a dissociation of peripheral and central effects of vasopressin.
    Gaffori O; de Wied D
    Psychoneuroendocrinology; 1985; 10(4):439-44. PubMed ID: 4089084
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vasopressin: site of behavioral action and role in human mental performance.
    Van Wimersma Greidanus TB; Veldhuis HD
    Peptides; 1985; 6 Suppl 2():177-80. PubMed ID: 4080615
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cysteinyl methyl ester of AVP(4-8), a potent agonist on the maintenance of passive avoidance in rats.
    Lin C; Liu RY; Du YC
    Peptides; 1990; 11(4):633-9. PubMed ID: 2235674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neonatal 6-hydroxydopa, but not DSP-4, elevates brainstem monoamines and impairs inhibitory avoidance learning in developing rats.
    Cornwell-Jones CA; Decker MW; Chang JW; Cole B; Goltz KM; Tran T; McGaugh JL
    Brain Res; 1989 Jul; 493(2):258-68. PubMed ID: 2504438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of fipexide on passive avoidance behaviour in rats.
    Serra G; Collu M; Martellotta MC; Forgione A; Fratta W
    Pharmacol Res; 1989; 21(5):603-8. PubMed ID: 2594616
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of vasopressin analog: [d(CH2)(1)5,Tyr(Me)2,delta 3Pro7]AVP on learning and memory processes in rats with experimental amnesia.
    Car H; Borawska M; Wiśniewski K
    Pol J Pharmacol; 1993; 45(1):11-22. PubMed ID: 8401755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of idebenone (CV-2619) on memory impairment observed in passive avoidance task in rats with cerebral embolization.
    Kiyota Y; Hamajo K; Miyamoto M; Nagaoka A
    Jpn J Pharmacol; 1985 Mar; 37(3):300-2. PubMed ID: 3999479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.